166 related articles for article (PubMed ID: 17266026)
1. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts.
Tait LR; Pauley RJ; Santner SJ; Heppner GH; Heng HH; Rak JW; Miller FR
Int J Cancer; 2007 May; 120(10):2127-34. PubMed ID: 17266026
[TBL] [Abstract][Full Text] [Related]
2. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ.
Casbas-Hernandez P; D'Arcy M; Roman-Perez E; Brauer HA; McNaughton K; Miller SM; Chhetri RK; Oldenburg AL; Fleming JM; Amos KD; Makowski L; Troester MA
Breast Cancer Res; 2013; 15(5):R82. PubMed ID: 24025166
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
4. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.
Shekhar MP; Nangia-Makker P; Tait L; Miller F; Raz A
Am J Pathol; 2004 Dec; 165(6):1931-41. PubMed ID: 15579437
[TBL] [Abstract][Full Text] [Related]
5. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
6. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.
Shekhar MP; Tait L; Pauley RJ; Wu GS; Santner SJ; Nangia-Makker P; Shekhar V; Nassar H; Visscher DW; Heppner GH; Miller FR
Cancer Biol Ther; 2008 Nov; 7(11):1774-82. PubMed ID: 18787417
[TBL] [Abstract][Full Text] [Related]
7. Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer.
Chang H; Mohabir N; Done S; Hamel PA
J Clin Pathol; 2009 Oct; 62(10):908-14. PubMed ID: 19783719
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. Invasion in breast lesions: the role of the epithelial-stroma barrier.
Rakha EA; Miligy IM; Gorringe KL; Toss MS; Green AR; Fox SB; Schmitt FC; Tan PH; Tse GM; Badve S; Decker T; Vincent-Salomon A; Dabbs DJ; Foschini MP; Moreno F; Wentao Y; Geyer FC; Reis-Filho JS; Pinder SE; Lakhani SR; Ellis IO
Histopathology; 2018 Jun; 72(7):1075-1083. PubMed ID: 29197112
[TBL] [Abstract][Full Text] [Related]
10. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
11. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).
Scribner KC; Behbod F; Porter WW
Oncogene; 2013 May; 32(21):2631-9. PubMed ID: 22777354
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
13. Consistent lack of CD34-positive stromal cells in the stroma of malignant breast lesions.
Kuroda N; Jin YL; Hamauzu T; Toi M; Miyazaki E; Hiroi M; Moriki T; Enzan H
Histol Histopathol; 2005 Jul; 20(3):707-12. PubMed ID: 15944918
[TBL] [Abstract][Full Text] [Related]
14. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer.
Schedin P; Borges V
Breast Cancer Res; 2009; 11(2):102. PubMed ID: 19344495
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of the tumor microenvironment during breast cancer progression.
Ma XJ; Dahiya S; Richardson E; Erlander M; Sgroi DC
Breast Cancer Res; 2009; 11(1):R7. PubMed ID: 19187537
[TBL] [Abstract][Full Text] [Related]
16. Columnar cell lesions and pseudoangiomatous hyperplasia like stroma: is there an epithelial-stromal interaction?
Recavarren RA; Chivukula M; Carter G; Dabbs DJ
Int J Clin Exp Pathol; 2009 Oct; 3(1):87-97. PubMed ID: 19918332
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast.
Yazhou C; Wenlv S; Weidong Z; Licun W
Tumour Biol; 2004; 25(5-6):290-5. PubMed ID: 15627894
[TBL] [Abstract][Full Text] [Related]
18. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer.
Bae YK; Kim A; Kim MK; Choi JE; Kang SH; Lee SJ
Hum Pathol; 2013 Oct; 44(10):2028-37. PubMed ID: 23684510
[TBL] [Abstract][Full Text] [Related]
19. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions.
Barth PJ; Ebrahimsade S; Ramaswamy A; Moll R
Virchows Arch; 2002 Mar; 440(3):298-303. PubMed ID: 11889601
[TBL] [Abstract][Full Text] [Related]
20. Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ.
Strell C; Paulsson J; Jin SB; Tobin NP; Mezheyeuski A; Roswall P; Mutgan C; Mitsios N; Johansson H; Wickberg SM; Svedlund J; Nilsson M; Hall P; Mulder J; Radisky DC; Pietras K; Bergh J; Lendahl U; Wärnberg F; Östman A
J Natl Cancer Inst; 2019 Sep; 111(9):983-995. PubMed ID: 30816935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
